{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:00:24Z","timestamp":1781114424546,"version":"3.54.1"},"reference-count":68,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Schizophrenia spectrum disorders (SSD) are a group of diseases characterized by one or more abnormal features in perception, thought processing and behavior. Patients suffering from SSD are at risk of developing life-threatening complications. Pharmacogenetic studies have shown promising results on personalized treatment of psychosis. In the current study, 103 patients diagnosed with SSD treated with risperidone as antipsychotic monotherapy were enrolled. Socio-demographics and clinical data were recorded, and laboratory tests and genotyping standard procedure for cytochrome P450 (CYP) 2D6*4 were performed. Patients were evaluated by the Positive and Negative Syndrome Scale (PANSS) on admission and at discharge. Based on the reduction in the PANSS total score, subjects were divided into non-responders, partial responders and full responders. Only 11 subjects had a full response to risperidone (10.67%), 53 subjects (51.45%) had a partial response, and 39 participants (37.86%) were non-responders. Patients at first episode psychosis showed significantly higher levels of blood glucose and prolactin levels, while chronic patients showed significantly higher LDL levels. Adverse drug reactions (ADR) such as tremor and stiffness significantly correlated with genetic phenotypes (p = 0.0145). While CYP2D6 showed no impact on treatment response, ADR were significantly more frequent among poor and intermediate metabolizers.<\/jats:p>","DOI":"10.3390\/ijms25126350","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T10:08:43Z","timestamp":1718014123000},"page":"6350","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Into a Deeper Understanding of CYP2D6\u2019s Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-3503","authenticated-orcid":false,"given":"Mariana","family":"Bondrescu","sequence":"first","affiliation":[{"name":"Department of Neurosciences-Psychiatry, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Timis County Emergency Clinical Hospital \u201cPius Brinzeu\u201d, Liviu Rebreanu 156, 300723 Timisoara, Romania"},{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Dehelean","sequence":"additional","affiliation":[{"name":"Department of Neurosciences-Psychiatry, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Timis County Emergency Clinical Hospital \u201cPius Brinzeu\u201d, Liviu Rebreanu 156, 300723 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Farcas","sequence":"additional","affiliation":[{"name":"Discipline of Medical Genetics, Department of Microscopic Morphology, Center of Genomic Medicine \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Alexandra","family":"Dragan","sequence":"additional","affiliation":[{"name":"Timis County Emergency Clinical Hospital \u201cPius Brinzeu\u201d, Liviu Rebreanu 156, 300723 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Andreea","family":"Podaru","sequence":"additional","affiliation":[{"name":"Independent Researcher, 300523 Timiosara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Popa","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-4234","authenticated-orcid":false,"given":"Nicoleta","family":"Andreescu","sequence":"additional","affiliation":[{"name":"Discipline of Medical Genetics, Department of Microscopic Morphology, Center of Genomic Medicine \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders DSM-5, American Psychiatric Publishing. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/schbul\/sbx056","article-title":"Lifetime Prevalence and Correlates of Schizophrenia-Spectrum, Affective, and Other Non-affective Psychotic Disorders in the Chinese Adult Population","volume":"43","author":"Chang","year":"2017","journal-title":"Schizophr. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.mppsy.2008.07.011","article-title":"Schizophrenia: Epidemiology and risk factors","volume":"7","author":"Oliver","year":"2008","journal-title":"Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Orrico-S\u00e1nchez, A., L\u00f3pez-Lacort, M., Mu\u00f1oz-Quiles, C., Sanf\u00e9lix-Gimeno, G., and D\u00edez-Domingo, J. (2020). Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. BMC Psychiatry, 20.","DOI":"10.1186\/s12888-020-02538-8"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"116305","DOI":"10.1016\/j.envres.2023.116305","article-title":"The global burden of schizophrenia and the impact of urbanization during 1990\u20132019: An analysis of the global burden of disease study 2019","volume":"232","author":"Li","year":"2023","journal-title":"Environ. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1080\/03007995.2021.1954894","article-title":"Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries","volume":"37","author":"Pilon","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.schres.2024.01.009","article-title":"Prevalence and 3-year incidence of physical illnesses after schizophrenia diagnosis: Comparison with general population","volume":"264","author":"Chen","year":"2024","journal-title":"Schizophr. Res."},{"key":"ref_9","unstructured":"(2024, April 12). WHO. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia."},{"key":"ref_10","first-page":"100118","article-title":"Beyond one-size-fits-all: The rise of personalized treatment in schizophrenia","volume":"43\u201344","author":"Nashwan","year":"2024","journal-title":"Pers. Med. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","article-title":"Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: Lack of impact of MDR-1 genotypes","volume":"57","author":"Mihara","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.29245\/2578-2959\/2018\/5.1138","article-title":"Fine Tuning the Use of Second Generation Antipsychotics","volume":"2","author":"Schwartz","year":"2018","journal-title":"J. Ment. Health Clin. Psychol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1742-1241.2007.01321.x","article-title":"Paliperidone: Quo vadis?: Paliperidone","volume":"61","author":"Citrome","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e7988","DOI":"10.17795\/ijpbs-7988","article-title":"Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study","volume":"10","author":"Samiei","year":"2016","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.schres.2014.12.024","article-title":"Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data","volume":"161","author":"Nakajima","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_16","first-page":"631690","article-title":"Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment","volume":"2011","author":"McGorry","year":"2011","journal-title":"Schizophr. Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/NDT.S14385","article-title":"Clinical utility of the risperidone formulations in the management of schizophrenia","volume":"7","author":"Madaan","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3889\/oamjms.2021.6333","article-title":"Total Cholesterol Levels in Men with Schizophrenia Receiving Risperidone and Haloperidol Treatment","volume":"9","author":"Agusmita","year":"2021","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ncl.2010.10.002","article-title":"Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial","volume":"29","author":"Caroff","year":"2011","journal-title":"Neurol. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40780-018-0126-y","article-title":"Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: A retrospective study","volume":"4","author":"Ito","year":"2018","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JCP.0000000000000464","article-title":"Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study","volume":"36","author":"Bo","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial","volume":"162","author":"Schooler","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.37506\/ijfmt.v15i2.14735","article-title":"Sinuraya Association of Genetic Polymorphisms with Risperidone Treatment Response in Schizophrenia: A Review","volume":"15","author":"Gina","year":"2021","journal-title":"Indian J. Forensic Med. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/1389201018666170224105600","article-title":"Clinical Applications of Personalized Medicine: A New Paradigm and Challenge","volume":"18","author":"Cipolloni","year":"2017","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"113058","DOI":"10.1016\/j.bbr.2020.113058","article-title":"Pharmacogenetics of antipsychotics: Clinical utility and implementation","volume":"401","author":"Arranz","year":"2021","journal-title":"Behav. Brain Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpsychires.2024.04.001","article-title":"Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review","volume":"174","author":"Budde","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"711940","DOI":"10.3389\/fphar.2021.711940","article-title":"Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone","volume":"12","author":"Zubiaur","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2174\/1389450043345263","article-title":"The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions","volume":"5","author":"Berecz","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of Atypical Antipsychotics: Involvement of Cytochrome P450 Enzymes and Relevance for Drug-Drug Interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_31","unstructured":"(2024, April 12). pharmgkb. Available online: https:\/\/www.pharmgkb.org\/chemical\/PA451257."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejps.2010.06.016","article-title":"A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia","volume":"41","author":"Locatelli","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","article-title":"Risperidone plasma levels, clinical response and side\u2013effects","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: A retrospective, cohort study","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/FPC.0b013e3283659a94","article-title":"CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment","volume":"23","author":"Almoguera","year":"2013","journal-title":"Pharmacogenet. Genom."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","article-title":"Applications of CYP450 Testing in the Clinical Setting","volume":"17","author":"Samer","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lu, J., Yang, Y., Lu, J., Wang, Z., He, Y., Yan, Y., Fu, K., Jiang, W., Xu, Y., and Wu, R. (2021). Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. BMC Psychiatry, 21.","DOI":"10.1186\/s12888-020-03034-9"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","article-title":"Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales","volume":"19","author":"Sistonen","year":"2009","journal-title":"Pharmacogenet. Genom."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-007-0445-7","article-title":"The CYP2D6 gene locus in South African Coloureds: Unique allele distributions, novel alleles and gene arrangements","volume":"64","author":"Gaedigk","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1469-1809.2010.00585.x","article-title":"Elucidation of CYP2D6 Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population","volume":"74","author":"Wright","year":"2010","journal-title":"Ann. Hum. Genet."},{"key":"ref_41","first-page":"40","article-title":"Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort","volume":"5","author":"Dodgen","year":"2015","journal-title":"Appl. Transl. Genom."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10517-016-3250-4","article-title":"CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects","volume":"160","author":"Ivanova","year":"2016","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_43","first-page":"131","article-title":"CYP2D6 polymorphisms and their influence on risperidone treatment","volume":"9","author":"Puangpetch","year":"2016","journal-title":"Pharmacogenomics Pers. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s11845-019-01985-x","article-title":"Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients","volume":"188","author":"Andreescu","year":"2019","journal-title":"Ir. J. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.psychres.2016.04.001","article-title":"Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia","volume":"240","author":"Charan","year":"2016","journal-title":"Psychiatry Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/IJPSYM.IJPSYM_83_18","article-title":"A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia","volume":"40","author":"Chavan","year":"2018","journal-title":"Indian J. Psychol. Med."},{"key":"ref_47","first-page":"128","article-title":"No association of rs1065852 and rs3892097 polymorphisms gene CYP2D6 with treatment resistant schizophrenia","volume":"4-1","author":"Sosin","year":"2019","journal-title":"Vm Bekhterev Rev. Psychiatry Med. Psychol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00228-010-0850-1","article-title":"The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na\u00efve patients with first-episode schizophrenia treated with risperidone","volume":"66","author":"Medved","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200503000-00002","article-title":"Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6","volume":"20","author":"Kakihara","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_50","first-page":"236","article-title":"Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone","volume":"33","year":"2012","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cojocaru, A., Braha, A., Jeleriu, R., Andreescu, N.I., Puiu, M., Ageu, L., Folescu, R., Zamfir, C.L., and Nussbaum, L.A. (2024). The Implications of Cytochrome P450 2D6\/CYP2D6 Polymorphism in the Therapeutic Response of Atypical Antipsychotics in Adolescents with Psychosis\u2014A Prospective Study. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030494"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","article-title":"Medication adherence in schizophrenia","volume":"2","author":"Acosta","year":"2012","journal-title":"World J. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1192\/bjp.184.6.509","article-title":"Non-adherence to antipsychotic medication regimens: Associations with resource use and costs","volume":"184","author":"Knapp","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","article-title":"Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis","volume":"9","author":"Semahegn","year":"2020","journal-title":"Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 Poor Metabolizer Phenotype May Be Associated With Risperidone Adverse Drug Reactions and Discontinuation","volume":"66","author":"Susce","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/phar.1634","article-title":"Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization","volume":"35","author":"Jiang","year":"2015","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3389\/fpsyt.2019.00633","article-title":"Association Study of KCNH7 Polymorphisms and Individual Responses to Risperidone Treatment in Schizophrenia","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3126\/jngmc.v18i1.35208","article-title":"Socio Demographic Profile and Risperidone Response in New Versus Old Schizophrenia Patients","volume":"18","author":"Belbase","year":"2020","journal-title":"J. Nepalgunj Med. Coll."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bcpt.12970","article-title":"Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder","volume":"123","author":"Sukasem","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tsai, H.-P., Hou, P.-H., Mao, F.-C., Chang, C.-C., Yang, W.-C., Wu, C.-F., Liao, H.-J., Lin, T.-C., Chou, L.-S., and Hsiao, L.-W. (2021). Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010409"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3329\/bmrcb.v41i3.29972","article-title":"Metabolic risk factor profile in patients on treatment with second generation antipsychotics","volume":"41","author":"Zahan","year":"2016","journal-title":"Bangladesh Med. Res. Counc. Bull."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Chen, K., Zhang, X.Y., Feng, W., Lu, Y., Xiu, M.H., and Chen, D.C. (2019). Effects of risperidone on glucose lipid metabolism and bodyweight in drug-na\u00efve first episode Chinese Han patients with schizophrenia: A prospective study. Res. Sq., Available online: https:\/\/www.researchsquare.com\/article\/rs-2876\/v1.","DOI":"10.21203\/rs.2.12083\/v1"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41598-021-83570-w","article-title":"Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone","volume":"11","author":"Hongkaew","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"106392","DOI":"10.1016\/j.psyneuen.2023.106392","article-title":"Blood concentrations of anterior pituitary hormones in drug-na\u00efve people with first-episode psychosis: A systematic review and meta-analysis","volume":"158","author":"Cavaleri","year":"2023","journal-title":"Psychoneuroendocrinology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2005.09.002","article-title":"Factor structure and external validity of the PANSS revisited","volume":"82","author":"Rujescu","year":"2006","journal-title":"Schizophr. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Turkoz, I., Li, H., and Zhang, F. (2015). Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: An open-label, prospective, noncomparative study. Neuropsychiatr. Dis. Treat., 15\u201324.","DOI":"10.2147\/NDT.S83651"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/acps.12849","article-title":"Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia","volume":"137","author":"Lin","year":"2018","journal-title":"Acta Psychiatr. Scand."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6350\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:55:47Z","timestamp":1760108147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":68,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25126350"],"URL":"https:\/\/doi.org\/10.3390\/ijms25126350","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,8]]}}}